We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02961491
Expanded Access Status : Approved for marketing
First Posted : November 11, 2016
Last Update Posted : January 30, 2019
Information provided by (Responsible Party):
Molecular Insight Pharmaceuticals, Inc.

Brief Summary:
The purpose of this sub-study is to provide expanded access of AZEDRA (Ultratrace Iobenguane I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with iobenguane-avid malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL).

Condition or disease Intervention/treatment
Pheochromocytoma Paraganglioma Drug: Ultratrace Iobenguane I131

Detailed Description:
MIP-IB12B, the pivotal phase 2 study evaluating efficacy and safety of AZEDRA in patients with malignant relapsed/refractory PPGL, has completed its anticipated enrollment. The purpose of this sub-study, MIP-IB12B-EAP, is to provide expanded access to AZEDRA for newly enrolled subjects with iobenguane-avid metastatic and/or recurrent PPGL and to collect additional safety data.

Layout table for study information
Study Type : Expanded Access
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access Program of AZEDRA (Ultratrace Iobenguane I131) in Subjects With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma: A Sub-study of Protocol MIP-IB12B

Intervention Details:
  • Drug: Ultratrace Iobenguane I131
    Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
    Other Names:
    • Azedra
    • MIBG

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Able and willing to provide informed consent/assent and comply with protocol requirements
  • Documented diagnosis of either pheochromocytoma or paraganglioma that was confirmed by histology or other supportive data (e.g. abnormal MIBG diagnostic study or elevated tumor markers)
  • Ineligible for curative surgery for PPGL
  • Failed a prior therapy for PPGL or have no alternative indicated therapy available
  • Have definitive tumor avidity confirmed by the AZEDRA dosimetry dose
  • Life expectancy of at least 6 months per physician

Exclusion Criteria:

  • Pregnant or nursing females
  • Men or women of childbearing potential and unwilling to use a medically acceptable form of contraception from time of consent until 6 months following last therapeutic dose of AZEDRA
  • Active CNS lesions by CT/MRI within 3 months of informed consent
  • NYHA class IV heart failure, unstable angina pectoris or clinically significant cardiac arrhythmia that poses a risk of syncope or cardiac arrest
  • Prior systemic radiotherapy resulting in marrow toxicity within 3 months of first AZEDRA therapeutic dose
  • Prior iobenguane I 131 therapeutic exposure within 12 weeks of the first planned therapeutic dose
  • Prior administration of whole-body radiation therapy within 12 weeks of the first planned therapeutic dose
  • Prior external beam radiotherapy to > 25% of bone marrow
  • Prior chemotherapy or investigational compound and/or device within 30 days of the dosimetry dose
  • Other active malignancy requiring additional treatment except for superficial cutaneous neoplasms
  • Karnofsky Performance Status < 60
  • Clinically significant laboratory abnormalities prior to dosing as listed in the protocol (such as blood count abnormalities, liver enzyme abnormalities, and renal dysfunction)
  • Medical history of AIDS/HIV+
  • Active chronic alcohol abuse, chronic liver disease (not including liver metastases), hepatitis A, B, or C
  • Known allergy to iobenguane that has required medical intervention
  • Receiving a medication which inhibits tumor uptake of iobenguane I 131
  • Any other condition, that in the opinion of the investigator, may compromise the safety or compliance of the subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02961491

Layout table for location information
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Molecular Insight Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Molecular Insight Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02961491    
Other Study ID Numbers: MIP-IB12B-EAP
First Posted: November 11, 2016    Key Record Dates
Last Update Posted: January 30, 2019
Last Verified: January 2019
Keywords provided by Molecular Insight Pharmaceuticals, Inc.:
Rare neuroendocrine tumors
Iobenguane I 131
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action